GABAA Gain-of-Function Mutation Triggers Seizures via Interneuron Network Collapse in Mice

The Paradox of Enhanced Inhibition in Epileptic Encephalopathy

Developmental and epileptic encephalopathies (DEE) represent a group of severe disorders where frequent, drug-resistant seizures contribute to progressive cognitive and motor impairment [1, 2]. While many of these conditions arise from loss-of-function mutations that reduce synaptic inhibition, clinicians are increasingly encountering variants in gamma-aminobutyric acid type A (GABAA) receptor subunits that paradoxically increase receptor activity [2, 3]. These gain-of-function mutations are often associated with earlier seizure onset, more profound intellectual disability, and a higher risk of treatment failure compared to their loss-of-function counterparts [2, 4]. The clinical management of these patients remains challenging because standard interventions designed to modulate neuronal excitability or protect the blood-brain barrier often fail to achieve seizure control [5, 3]. A new study now offers fresh insights into the specific physiological mechanisms that transform enhanced inhibition into a driver of network hyperexcitability.

Modeling the Human GABRB3 Variant in Vivo

The clinical landscape of developmental and epileptic encephalopathy is increasingly defined by gain-of-function variants in GABAA receptors, which are now recognized as a primary cause of these severe neurological conditions. To investigate the pathophysiology of these disorders, researchers engineered a specific mouse model based on the human GABRB3 p.(Glu77Lys) variant, designated as the β3E77K model. This specific genetic variant was originally identified in two individuals diagnosed with developmental and epileptic encephalopathy, providing a direct link between the experimental model and the clinical presentation of the disease. The impact of the gain-of-function mutation was evident from the earliest stages of development, as the researchers observed that β3E77K mice exhibited embryonic lethality. This finding underscores the severe early developmental impact of the gain-of-function GABAA receptor variant, suggesting that enhanced inhibitory signaling disrupts essential neurodevelopmental processes long before the onset of postnatal seizures. For the mice that survived into the postnatal period, the mutation resulted in a distinct set of physical and behavioral impairments that mirror the global developmental delays often seen in human patients. Comprehensive neurological assessments of the surviving β3E77K mice further characterized the functional consequences of the mutation, finding that these animals displayed significant hypoactivity, characterized by a marked reduction in spontaneous movement and exploration. Additionally, the researchers documented weakened grip-strength in the β3E77K cohort, indicating that the GABRB3 p.(Glu77Lys) variant contributes to motor deficits alongside the expected seizure phenotype. These findings establish the β3E77K mouse as a robust preclinical model for studying how specific gain-of-function mutations in inhibitory receptors translate into the complex clinical symptoms of developmental and epileptic encephalopathy.

Electrophysiological Evidence of Cortical Hyperexcitability

Electrocorticography (ECoG), a method of recording electrical activity directly from the cerebral cortex, revealed a distinct neurophysiological profile in the mutant mice. The β3E77K mice displayed spontaneous spike-wave-like discharges, which are rhythmic, high-amplitude electrical patterns often associated with absence-type seizures and impaired consciousness. Beyond these discrete events, the study found a broad increase in ECoG spectral power amplitude across the frequency spectrum. This elevation in total electrical power serves as a definitive marker of cortical hyperexcitability, suggesting that the gain-of-function mutation creates a baseline state of neuronal over-activation despite the mutation's role in enhancing inhibitory receptor function. To further explore the paradoxical nature of this hyperexcitability, the authors conducted pharmacological challenges that mirrored clinical treatment protocols for developmental and epileptic encephalopathy. They found that the spike-wave-like discharges in β3E77K mice were exacerbated by vigabatrin, an anticonvulsant that increases GABA levels by inhibiting the enzyme GABA transaminase. Conversely, these discharges were ameliorated by valproate, a broad-spectrum anti-seizure medication. This pharmacological response is highly significant for clinicians, as it matches the specific clinical observations of patients with GABRB3 gain-of-function variants, where increasing GABA availability through medications like vigabatrin can inadvertently worsen the seizure phenotype. The study also assessed the threshold for acute seizure activity by exposing the animals to chemical triggers, finding that β3E77K mice showed increased proconvulsant-induced seizure susceptibility. This demonstrates that the underlying cortical instability makes the brain more vulnerable to external stressors. This heightened sensitivity, combined with the ECoG evidence of persistent spectral power increases, confirms that the GABRB3 p.(Glu77Lys) variant fundamentally alters the network balance, leading to a state of chronic hyperexcitability and a lowered seizure threshold that responds poorly to conventional GABA-enhancing therapies.

The Mechanism of Feed-Forward Inhibition Collapse

Ex-vivo electrophysiological recordings, a technique that measures electrical activity in living tissue slices to assess synaptic function, were used to delineate the cellular basis of the observed hyperexcitability. In the CA1 region of the hippocampus, a brain area frequently involved in seizure generation, the study found increased GABAA receptor-mediated current amplitudes at both excitatory and inhibitory synapses. These findings confirm the gain-of-function molecular phenotype of the β3E77K mutation, demonstrating that the receptor's response to the inhibitory neurotransmitter GABA is pathologically enhanced across different neuronal connections. The investigation of cortical layer 2/3 revealed a critical circuit-level paradox that explains the transition from enhanced inhibition to network-wide over-activation. While inhibitory interneurons in cortical layer 2/3 showed increased synaptic GABAA receptor-mediated current amplitude, the synapses onto pyramidal neurons (the primary excitatory cells of the cortex) exhibited reduced inhibitory currents. This discrepancy occurs because the enhanced GABAA receptor-mediated synaptic activity among layer 2/3 interneuron populations caused a use-dependent collapse of feed-forward inhibition. Feed-forward inhibition is the physiological process where inhibitory neurons are activated to dampen the excitation of principal neurons; in these mutant mice, the interneurons inhibit each other so effectively that they fail to provide the necessary inhibitory output to the rest of the circuit. This failure of the inhibitory network directly resulted in increased pyramidal neuron excitability, providing a clear cellular mechanism for the seizures observed in patients with developmental and epileptic encephalopathy. To validate these biological observations, the authors utilized computational modelling, a mathematical simulation of neuronal activity, which confirmed that enhanced GABAA receptor synaptic strength between interneurons diminishes inhibitory synaptic conductance onto pyramidal cells. Collectively, these data demonstrate that interneuron network dysfunction drives cortical hyperexcitability in gain-of-function GABAA receptor variants, suggesting that the clinical phenotype arises not from a simple excess of inhibition, but from a catastrophic failure of the network's internal regulatory balance.

References

1. Traub‐Weidinger T, Arbizu J, Barthel H, et al. EANM practice guidelines for an appropriate use of PET and SPECT for patients with epilepsy. European Journal of Nuclear Medicine and Molecular Imaging. 2024. doi:10.1007/s00259-024-06656-3

2. Absalom NL, Liao VWY, Johannesen KM, et al. Gain-of-function and loss-of-function GABRB3 variants lead to distinct clinical phenotypes in patients with developmental and epileptic encephalopathies. Nature Communications. 2022. doi:10.1038/s41467-022-29280-x

3. Maillard P, Baer S, Schaefer É, et al. Molecular and clinical descriptions of patients with GABA_A receptor gene variants (GABRA1, GABRB2, GABRB3, GABRG2): A cohort study, review of literature, and genotype–phenotype correlation. Epilepsia. 2022. doi:10.1111/epi.17336

4. Butler KM, Moody OA, Schuler E, et al. De novo variants in GABRA2 and GABRA5 alter receptor function and contribute to early-onset epilepsy. Brain. 2018. doi:10.1093/brain/awy171

5. Huang N, Huang Y, Deng Z, et al. Blood‑brain barrier dysfunction in epilepsy: Mechanisms, therapeutic strategies and future orientation (Review). International Journal of Molecular Medicine. 2025. doi:10.3892/ijmm.2025.5577